Home

Articles from SinoMab BioScience Limited

SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
By SinoMab BioScience Limited · Via ACN Newswire · April 9, 2025
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
HONG KONG, Dec 19, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Company was awarded the "Most Valuable Pharmaceutical and Medical Company" at the "7th Hong Kong Golden Stocks Awards Ceremony" held in Hangzhou today.
By SinoMab BioScience Limited · Via ACN Newswire · December 19, 2022
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
By SinoMab BioScience Limited · Via ACN Newswire · March 14, 2022
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
By SinoMab BioScience Limited · Via ACN Newswire · February 17, 2022
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
By SinoMab BioScience Limited · Via ACN Newswire · February 7, 2022
SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong
By SinoMab BioScience Limited · Via ACN Newswire · January 11, 2022
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
By SinoMab BioScience Limited · Via ACN Newswire · November 30, 2021
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
By SinoMab BioScience Limited · Via ACN Newswire · November 26, 2021
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
By SinoMab BioScience Limited · Via ACN Newswire · September 17, 2021